As the cloud moved away from the tent, Miriam’s skin suddenly became diseased, as white as snow. When Aaron turned toward her, he saw that she was diseased. —Numbers 12:10 For 29 years he [Fray Pedro de Urraca] was afflicted by … pain, suffering it at once in all the joints of his body, with…
Real-Life Rheumatology: Clinical Pearls for Psoriatic Arthritis
At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Ana-Maria Orbai, MD, MHS, discussed lessons learned from the cases of several patients with psoriatic arthritis.
Pregnancy Outcomes in Patients with Psoriatic Arthritis
In March A&R, Remaeus et al. reported on the results of their study, which evaluated pregnancy outcomes in relation to anti-rheumatic treatment before and during pregnancy, as a proxy of disease severity in pregnant women with psoriatic arthritis (PsA), compared with those without PsA.
How Do Axial SpA & PsA with Axial Involvement Differ?
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
Risankizumab Effective Against Refractory Psoriatic Arthritis
NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…
The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.
Reproductive Health & PsA: New ACR Training Program Enhances Provider Education
The ACR has developed educational materials for healthcare providers to use to discuss reproductive health and contraception with their patients with psoriatic arthritis.
New Supplement to The Rheumatologist Highlights Psoriatic Arthritis Advances
It feels like a long decade has passed since March 2020. At The Rheumatologist, we closed out 2020 with a special supplement on gout. Physician Editor Phil Seo, MD, MHS, kicked off that supplement with, “COVID-19. Black Lives Matter. A new gout guideline. These are some of the things 2020 ushered in. And we’re unlikely…
Minimizing Disease Activity in Psoriatic Arthritis
The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and…
A Dematologist’s Perspective on Choosing an Anti-Psoriatic Drug
We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 15
- Next Page »